Pilot Trial of Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Allogeneic Transplant

Trial Profile

Pilot Trial of Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Allogeneic Transplant

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Vorinostat (Primary) ; Methotrexate; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Aug 2017 Results published in the Blood
    • 10 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top